Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00136539
Status:
COMPLETED
Last Update Posted:
2013-02-18
First Post:
2005-08-26
Brief Title:
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
Sponsor:
Harold J Burstein MD PhD
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
98-222
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Harold J Burstein MD PhD
Lead Sponsor Class:
OTHER
Responsible Party:
Harold J Burstein MD PhD
Responsible Party Title:
Associate Professor of Medicine
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Dana-Farber Cancer Institute | OTHER |
| Genentech Inc | INDUSTRY |
| Bristol-Myers Squibb | INDUSTRY |
| Massachusetts General Hospital | OTHER |
| Beth Israel Deaconess Medical Center | OTHER |
| Harvard Vanguard Medical Associates | OTHER |
| Brigham and Womens Hospital | OTHER |